EssilorLuxottica, a leading player in the optics industry, continues its expansion in Europe with the acquisition of Signifeye, an established ophthalmology platform in Belgium. This transaction follows the recent purchase of Optegra, which operates over 70 clinics across several European countries. The integration of Signifeye is expected to strengthen EssilorLuxottica's presence in the ophthalmic care sector.
Enhancing Medical Services
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
According to the press release, Signifeye offers medical services in 15 clinics throughout Flanders, covering a wide range of eye health services. The acquisition is part of EssilorLuxottica's strategy to develop an integrated and innovative medical model, capable of meeting the diverse needs of patients in terms of eye care. The integration of Signifeye into the EssilorLuxottica ecosystem is also expected to enhance patient experience.
Strengthening Market Position
EssilorLuxottica views this acquisition as a way to strengthen Optegra's position in Europe and to advance in its med-tech trajectory. The completion of this transaction is expected by the first quarter of 2026. EssilorLuxottica's leaders, Francesco Milleri and Paul du Saillant, along with Signifeye's General Manager, Kathleen Moons, have expressed optimism about this new phase of joint development.
C’est une année historique pour EssilorLuxottica : pour la première fois depuis l’origine du Groupe, notre chiffre d’affaires a enregistré une croissance à deux chiffres à taux de change constant, après un quatrième trimestre affichant une croissance record de 18,4 %.
Résultats annuels 2025 marquent une croissance du chiffre d’affaires de 11,2% et une marge opérationnelle ajustée de 15,7%; le cash-flow libre atteint 2,8 milliards d'euros; dividende proposé de 4,00 euros; acquisitions et initiatives med-tech renforcent le positionnement.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
